References
- Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets Therap. 2013;3:1–10
- Villaseñor-Park J, Wheeler D, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Cleve Clin J Med. 2012;79:413–23
- Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:il 14–17
- Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–24
- Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician. 2000;61:725–33
- Rácz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol. 2011;131:1547–58
- Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderated to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol. 2011;165:640–5
- Lee Y, Baron ED. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg. 2011;30:199–209
- Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet. 1994;343:801
- Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 1: photochemistry and photobiology. J Eur Acad Dermatol Venereol. 2007;21:293–302
- Kurwa HA, Barlow RJ. The role of photodynamic therapy in dermatology. Clin Exp Dermatol. 1999;24:143–8
- Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs. 2008;2008:1–24
- Tandon YK, Yang MF, Baron ED. Role of photodynamic therapy in psoriasis: a brief review. Photodermatol Photoimmunol Photomed. 2008;24:222–30
- Collins P, Robinson DJ, Stringer MR, et al. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 1997;137:743–9
- Robinson DJ, Collins P, Stringer MR, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol. 1999;79:451–5
- Bissonnette R, Tremblay JF, Juzenas P, et al. Systemic photodynamic therapy with aminolevulinic acid induced apoptosis in lesional T lymphocytes of psoriatic plaques. J Invest Dermatol. 2002;119:77–83
- Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clin Exp Dermatol. 2004;29:560–2
- Fransson J, Ros AM. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy. Photodermatol Photoimmunol Photomed. 2005;21:326–32
- Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V, et al. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol. 2005;152:279–83
- Schleyer V, Radakovic-Fijan S, Karrer S, et al. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol. 2006:20:823–8
- Smits T, Kleinpenning MM, van Erp PEJ, et al. A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. Br J Dermatol. 2006;155:429–36
- Kleinpenning MM, Kanis JH, Smits T, et al. The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis. J Dermatolog Treat. 2010;21:245–51
- Maytin EV, Honari G, Khachemoune A, et al. Vitamin D combined with aminolevulinate (ALA)-mediated photodynamic therapy (PDT) for human psoriasis: a proof-of-principle study. Isr J Chem. 2012;52:767–75
- Schick E, Rück A, Boehncke WH, Kaufmann R. Topical photodynamic therapy using methylene blue and 5-aminolaevulinic acid in psoriasis. J Dermatol Treat. 1997;8:17–19
- Boehncke WH, Elshorst-Schmidt T, Kaufmann R. Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol. 2000;136:271–2
- Salah M, Samy N, Fadel M. Methylene blue mediated photodynamic therapy for resistant plaque psoriasis. J Drugs Dermatol. 2009;8:42–9
- Rook AH, Wood GS, Duvic M, et al. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63:984–90
- Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol. 2009;61:1033–43
- Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–66
- Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:22–31
- Takahashi H, Nakajima S, Sakata I, et al. Photodynamic therapy using a novel photosensitizer, ATX-S10(Na): comparative effect with 5-aminolevulinic acid on squamous cell carcinoma line, SCC15, ultraviolet B-induced skin tumor, and phorbol ester-induced hyperproliferative skin. Arch Dermatol Res. 2005;296:496–502
- Baron ED, Malbasa CL, Santo-Domingo D, et al. Silicon phthalocyanine (Pc4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Laser Surg Med. 2010;42:728–35